Full Press Release Details
IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First Patient In for Multiple Combination Cohorts in MTAP Deletion Tumors.
IDYA
IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First Patient In for Multiple Combination Cohorts in MTAP Deletion Tumors
Key Takeaway: IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First Patient In for Multiple Combination Cohorts in MTAP Deletion Tumors
Price reaction · baseline $15.84 (2022-10-17 close) · hit after-hours · clean, no other IDYA news in the window
day 0 close
+0.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma